<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03954873</url>
  </required_header>
  <id_info>
    <org_study_id>H-18046965</org_study_id>
    <nct_id>NCT03954873</nct_id>
  </id_info>
  <brief_title>Glucagon-like Peptide 2 - a Glucose Dependent Glucagonotropic Hormone?</brief_title>
  <acronym>GLANCE</acronym>
  <official_title>Glucagon-like Peptide 2 - a Glucose Dependent Glucagonotropic Hormone?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Gentofte, Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Gentofte, Copenhagen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Infusion of glucagon-like peptide 2 (GLP-2) during euglycaemia, hypoglycaemia and
      hyperglycaemia and evaluation of the effect on glucagon secretion in healthy subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a cross-over, randomized, double-blinded study in which 10 participants will undergo
      6 experimental days each. The participants will have their plasma glucose clamped at either
      euglycaemia (fasting level), hypoglycemia (2,5 mmol/l) or hyperglycemia (10 mmol/l) during
      infusion of GLP-2 or saline (placebo)

      The six days will be as follows:

        -  Euglycaemia + Placebo

        -  Euglycaemia + GLP-2

        -  Hyperglycaemia + Placebo

        -  Hyperglycaemia + GLP-2

        -  Hypoglycaemia + Placebo

        -  Hypoglycaemia + GLP-2

      The primary endpoint will be levels of plasma glucagon. Secondary endpoint will be levels of
      GLP-1, GLP-2, Insulin/C-peptide, OXM, Amino acids, CCK, Gastrin, norepinephrine, bile acids,
      FGF-19/FGF-21. Secondary endpoints will also include ultrasound scan of the gallbladder.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 31, 2019</start_date>
  <completion_date type="Anticipated">May 29, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 29, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glucagon secretion</measure>
    <time_frame>110 minutes</time_frame>
    <description>Assessed by difference in absolute plasma glucagon concentrations (measured in pmol/liter) and incremental (baseline-subtracted) area under curve (AUC) for plasma glucagon</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma glucose</measure>
    <time_frame>110 minutes</time_frame>
    <description>Measured in mmol/liter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GLP-1</measure>
    <time_frame>110 minutes</time_frame>
    <description>Glucagon-like peptide 1, Measured in pmol/liter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GLP-2</measure>
    <time_frame>110 minutes</time_frame>
    <description>Glucagon-like peptide 2, Measured in pmol/liter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin</measure>
    <time_frame>110 minutes</time_frame>
    <description>Measured in pmol/liter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GIP</measure>
    <time_frame>110 minutes</time_frame>
    <description>Glucose dependent insulinotropic hormone, Measured in pmol/liter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OXM</measure>
    <time_frame>110 minutes</time_frame>
    <description>Oxytomodulin, Measured in pmol/liter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amino acids</measure>
    <time_frame>110 minutes</time_frame>
    <description>Measured in pmol/liter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CCK</measure>
    <time_frame>110 minutes</time_frame>
    <description>Cholecystokinin, Measured in pmol/liter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastrin</measure>
    <time_frame>110 minutes</time_frame>
    <description>Measured in pmol/liter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FGF-19</measure>
    <time_frame>110 minutes</time_frame>
    <description>Fibroblast Growth factor 19, Measured in ng/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FGF-21</measure>
    <time_frame>110 minutes</time_frame>
    <description>Fibroblast Growth factor 21, Measured in ng/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bile acids</measure>
    <time_frame>110 minutes</time_frame>
    <description>Measured in nmol/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Norepinephrine</measure>
    <time_frame>110 minutes</time_frame>
    <description>Measured in pmol/liter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GH</measure>
    <time_frame>110 minutes</time_frame>
    <description>Growth hormone, Measured in nmol/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>P1NP</measure>
    <time_frame>110 minutes</time_frame>
    <description>Procollagen type I N-terminal propeptide (Bonemarker), Measured in nmol/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CTX</measure>
    <time_frame>110 minutes</time_frame>
    <description>C-terminal telopeptide (Bonemarker), Measured in nmol/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gallbladder ultrasound</measure>
    <time_frame>110 minutes</time_frame>
    <description>Measuring of gallbladder size in respons to GLP-2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose infusion</measure>
    <time_frame>90 minutes</time_frame>
    <description>Amount of glucose infusion (20% v/w) in milliliters needed to clamp at isoglycemic levels (hyperglycemia and hypoglycemia) in respons to GLP-2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>110 minutes</time_frame>
    <description>Systolic (mmHg) and diastolic (mmHg) blood pressure in respons to GLP-2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate</measure>
    <time_frame>110 minutes</time_frame>
    <description>Heart rate (beats/minutes) in respons to GLP-2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-peptide</measure>
    <time_frame>110 minutes</time_frame>
    <description>Measured in pmol/liter</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Glucose Metabolism Disorders</condition>
  <condition>Endocrine or Metabolic Disease</condition>
  <arm_group>
    <arm_group_label>Hyperglycaemia + GLP-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Glucose + GLP-2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hyperglycaemia + Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Glucose + saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hypoglycaemia + GLP-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Insulin + glucose + GLP-2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hypoglycaemia + Saline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Insulin + glucose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Euglycaemia + GLP-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GLP-2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Euglycaemia + Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Glucagon-like peptide 2</intervention_name>
    <description>Human glucagon-like peptide 2</description>
    <arm_group_label>Euglycaemia + GLP-2</arm_group_label>
    <arm_group_label>Hyperglycaemia + GLP-2</arm_group_label>
    <arm_group_label>Hypoglycaemia + GLP-2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Euglycaemia + Placebo</arm_group_label>
    <arm_group_label>Hyperglycaemia + Placebo</arm_group_label>
    <arm_group_label>Hypoglycaemia + Saline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Glucose</intervention_name>
    <description>20% (w/v) glucose infusion for regulating plasma glucose</description>
    <arm_group_label>Hyperglycaemia + GLP-2</arm_group_label>
    <arm_group_label>Hyperglycaemia + Placebo</arm_group_label>
    <arm_group_label>Hypoglycaemia + GLP-2</arm_group_label>
    <arm_group_label>Hypoglycaemia + Saline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Insulin</intervention_name>
    <description>Actrapid (insulin) for lowering plasma glucose</description>
    <arm_group_label>Hypoglycaemia + GLP-2</arm_group_label>
    <arm_group_label>Hypoglycaemia + Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Caucasian ethnicity

          -  Body mass index (BMI): 18.5-27 kg/m2

          -  Glycated haemoglobin (HbA1c) &lt; 42 mmol/mol

          -  Normal haemoglobin (8.3-10.5 mmol/l)

          -  Informed and oral and written consent

        Exclusion Criteria:

          -  Prediabetes, type 1 diabetes or type 2 diabetes or first-degree relatives with type 1
             or type 2 diabetes

          -  Nephropathy (eGFR &lt; 60 and/or albuminuria)

          -  Known liver disease and/or alanine transaminase (ALAT) or aspartate transaminase
             (ASAT) &gt; 2 × upper normal limit

          -  Bilirubin &gt; 25 μmol/l

          -  Known intestinal disease or previous surgery of the intestines

          -  Active or recent malignant disease

          -  Treatment with medicine that cannot be paused for 12 hours

          -  Any condition considered incompatible with participation by the investigators
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Filip Krag Knop, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Center for Clinical Metabolic Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center for Clinical Metabolic Research</name>
      <address>
        <city>Hellerup</city>
        <state>Copenhagen</state>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>May 15, 2019</study_first_submitted>
  <study_first_submitted_qc>May 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 17, 2019</study_first_posted>
  <last_update_submitted>August 15, 2019</last_update_submitted>
  <last_update_submitted_qc>August 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Gentofte, Copenhagen</investigator_affiliation>
    <investigator_full_name>Filip Krag Knop</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>GLP-2</keyword>
  <keyword>Glucagon</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Diseases</mesh_term>
    <mesh_term>Glucose Metabolism Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucagon</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>IPD will not be shared with other researchers unless data management agreements are signed.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

